Stoke Therapeutics Inc. STOK
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Stoke Therapeutics Inc. is a biotechnology company focused on developing RNA-based medicines to treat the underlying causes of severe genetic diseases. It employs its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) platform, which uses antisense oligonucleotides to upregulate protein expression from he…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees170
TickerSTOK
Statistics
Market Cap$1.85B
Revenue (TTM)$184.4M
Net Income-$6.9M
Net Margin-3.7%
EPS$-0.12
P/E48.81
P/S57.00
P/B4.63
EV/EBITDA-7.81
ROE-45.6%
Dividend Yield—
Price$29.69
Data: Twelve Data · Revenue = mcap / P/S